EGFR and neoplasm: In our study of P13, the first primary tumor (squamous cell carcinoma) was observed in November 2018; the second tumor (adenocarcinoma) with an EGFR L858R mutation was observed in March 2019, and the patient was diagnosed with MPLC; the third tumor (squamous cell carcinoma) was observed in October 2019 and had the same pathology as the first tumor (Figures 8A, B).